Article citationsMore>>

Seipel, K., Brügger, Y., Mandhair, H., Bacher, U. and Pabst, T. (2022) Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid Leukemia. International Journal of Molecular Sciences, 23, Article No. 12587. https://doi.org/10.1182/blood-2016-07-692707

has been cited by the following article:

SCIRP Newsletter
Copyright © 2006-2026 Scientific Research Publishing Inc. All Rights Reserved.
Top